Europe Tissue Diagnostics Market Size, Trends and Insights By Technology (In Situ Hybridization, Immunohistochemistry, Digital Pathology and workflow, Primary and Special Staining, Anatomic Pathology), By Application (Prostate Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Other Cancer), By End Users (Research Laboratories, Hospitals, Contract Research Organizations (CROs), Pharmaceutical Organizations), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Europe |
| Largest Market: | Europe |
Major Players
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Agilent Technologies Inc.
- Others
Reports Description
As per the current market research conducted by the CMI Team, the Europe Tissue Diagnostics Market is expected to record a CAGR of 7.4% from 2023 to 2032. In 2023, the market size is projected to reach a valuation of USD 1,244.2 Million. By 2032, the valuation is anticipated to reach USD 2,375.4 Million.
The Europe Tissue Diagnostics Market encompasses the industry involved in the precise examination and analysis of tissue samples for accurate disease detection and diagnosis. Key players, including Roche Diagnostics and Thermo Fisher Scientific, contribute to advancements through technologies like digital pathology and molecular diagnostics.
Trends driving the market include a focus on personalized medicine, integration of artificial intelligence, and an increasing emphasis on early disease detection. With a growing aging population and continuous research investments, the market plays a pivotal role in enhancing healthcare outcomes by offering sophisticated diagnostic solutions tailored to individual patient needs.
Europe Tissue Diagnostics Market – Significant Growth Factors
The Europe Tissue Diagnostics Market presents significant growth opportunities due to several factors:
- Increasing Incidence of Chronic Diseases: The rising prevalence of chronic diseases, particularly cancer, is a major driver. Tissue diagnostics play a crucial role in early detection and accurate diagnosis, contributing to effective disease management and treatment.
- Aging Population: The demographic shift toward an aging population in Europe increases the incidence of age-related diseases, fostering the demand for tissue diagnostics and supporting market growth.
- Government Initiatives and Funding: Supportive government initiatives, coupled with increased funding for healthcare infrastructure and research, create a favorable environment for the expansion of the tissue diagnostics market in Europe.
- Integration of Artificial Intelligence (AI): Leveraging AI in tissue diagnostics presents an opportunity for enhanced data analysis, improved diagnostic accuracy, and streamlined pathology workflows, contributing to the market’s evolution.
- Collaborations and Research Partnerships: Opportunities lie in collaborations between industry players, research institutions, and healthcare providers. Strategic partnerships can lead to the development of innovative diagnostic solutions, addressing unmet needs and expanding the market’s capabilities.
- Advancements in Technology: Continuous technological innovations, such as digital pathology and molecular diagnostics, drive the Europe Tissue Diagnostics Market. These advancements enhance diagnostic precision, improve workflow efficiency, and contribute to the overall growth of the market.
- Collaborations and Strategic Partnerships: Collaborative efforts between healthcare institutions, diagnostic companies, and technology firms drive market growth. Strategic partnerships facilitate the development of integrated solutions, combining diagnostic technologies with healthcare systems, thereby enhancing the overall efficiency and accessibility of tissue diagnostics services.
Europe Tissue Diagnostics Market – Mergers and Acquisitions
The Europe Tissue Diagnostics Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Europe Tissue Diagnostics Market include:
- In 2023, Agilent Technologies, Inc. partnered with Akoya Biosciences, Inc. to co-develop multiplex immunohistochemistry (IHC) diagnostic solutions. This collaboration aims to commercialize workflow solutions for multiplex assays in tissue analysis, offering an advanced multiplex IHC solution for biomarker clinical research, leveraging the capabilities of digital pathology.
- In 2022, F. Hoffmann-La Roche Ltd obtained FDA approval for its PATHWAY anti-HER2/neu (485) Rabbit Monoclonal Primary Antibody. This antibody serves as a companion diagnostic test, aiding in the identification of metastatic breast cancer patients exhibiting low HER2 expression. The approval enhances precision in determining suitable treatment strategies for this specific patient population.
- In 2021, Roche introduced the DISCOVERY Green HRP Chromogen Detection Kit, aiming to broaden immunohistochemistry multiplexing capabilities in cancer research. This kit enhances the detection of multiple biomarkers simultaneously, facilitating more comprehensive and detailed analysis in the field of cancer diagnostics and research.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Europe Tissue Diagnostics Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Europe Tissue Diagnostics Market | India Pharmaceutical Market | DNA Nanotechnology Market |
| CAGR 7.4% (Approx) | CAGR 9.48% (Approx) | CAGR 18.5% (Approx) |
| USD 2,375.4 Million by 2032 | USD 129.49 Billion by 2032 | USD 29.2 Billion by 2032 |
Europe Tissue Diagnostics Market – Significant Threats
The Europe Tissue Diagnostics Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Data Privacy Concerns: The increasing reliance on digital pathology and electronic health records raises concerns about data security and patient privacy. Cybersecurity threats and data breaches can undermine confidence in tissue diagnostics technologies, potentially affecting market acceptance and adoption.
- High Implementation Costs: The initial costs associated with implementing advanced tissue diagnostic technologies can be substantial. This financial barrier may limit the adoption of advanced diagnostic solutions, especially for smaller healthcare facilities, impacting market growth.
- Competition from Alternative Diagnostic Methods: Emerging alternative diagnostic methods, such as liquid biopsies and molecular diagnostics, pose a threat to traditional tissue diagnostics. These alternatives offer less invasive approaches, potentially diverting demand away from traditional tissue-based diagnostic methods and affecting market share.
- Supply Chain Disruptions: The tissue diagnostics market relies on a complex global supply chain for reagents, equipment, and consumables. Disruptions in the supply chain, whether due to geopolitical events, natural disasters, or global health crises, can adversely impact the availability of essential components, leading to market constraints.
- Regulatory Challenges: Evolving and stringent regulatory requirements in European healthcare pose a significant threat to the Tissue Diagnostics Market. Compliance with changing regulations may increase operational costs and create hurdles in product approvals and market entry.
Category-Wise Insights
By Technology:
- In Situ Hybridization (ISH): ISH in the Europe Tissue Diagnostics Market involves localizing nucleic acid sequences within tissue samples. Trends include an increasing focus on RNA ISH techniques for gene expression analysis and the integration of automated platforms, enhancing diagnostic accuracy and efficiency.
- Immunohistochemistry (IHC): IHC is a technique detecting antigens in tissues. In Europe, trends involve the adoption of multiplex IHC for simultaneous biomarker analysis, driving precision medicine applications and enabling comprehensive tissue characterization for improved patient stratification.
- Digital Pathology and Workflow: Digital pathology in Europe’s Tissue Diagnostics Market refers to the digitization of pathology slides. Trends include the widespread adoption of whole-slide imaging, AI-assisted analysis, and integrated workflow solutions, streamlining diagnostic processes and facilitating remote collaboration among pathologists.
- Primary and Special Staining: Primary and special staining in the Europe Tissue Diagnostics Market involves techniques to enhance tissue visualization. Trends include a shift towards automation, reducing turnaround times, and increasing standardization, promoting consistency and accuracy in staining procedures.
- Anatomic Pathology: Anatomic pathology within the Europe Tissue Diagnostics Market encompasses the study of tissue structures for disease diagnosis. Trends involve advancements in histopathology, molecular diagnostics integration, and personalized medicine applications, contributing to more precise and tailored patient care.
By Application
- Prostate Cancer: In the Europe Tissue Diagnostics Market, prostate cancer application involves the examination of prostate tissue for diagnosis and treatment planning. Trends include an increasing focus on personalized medicine, utilizing tissue diagnostics to identify specific biomarkers for tailored therapeutic approaches.
- Breast Cancer: Breast cancer tissue diagnostics in Europe encompass the analysis of breast tissue for accurate diagnosis and prognostic information. Trends involve the integration of digital pathology, molecular diagnostics, and an emphasis on early disease detection for improved patient outcomes.
- Lung Cancer: In the European Tissue Diagnostics Market, lung cancer application entails the examination of lung tissue for precise diagnosis and treatment guidance. Trends include advancements in molecular diagnostics, targeted therapies, and the integration of artificial intelligence for enhanced diagnostic accuracy.
- Gastric Cancer: Gastric cancer tissue diagnostics in Europe involve the study of stomach tissue to identify malignancies. Trends include the adoption of advanced imaging techniques, molecular profiling for targeted therapies, and the incorporation of telepathology to streamline diagnostics and facilitate collaborative approaches.
- Other Cancer: The broader category of “Other Cancer” tissue diagnostics involves the examination of tissues from various organs for cancer detection and characterization. Trends encompass a growing emphasis on comprehensive biomarker analysis, collaborative research initiatives, and advancements in multiplex immunohistochemistry for detailed tissue analysis.
By End User
- Research Laboratories: Research laboratories in Europe Tissue Diagnostics Market conduct in-depth studies to develop and enhance diagnostic technologies. Trends include a focus on molecular diagnostics, automation for efficiency, and collaborative projects with industry players to advance diagnostic capabilities.
- Hospitals: Hospitals are crucial end-users in the Tissue Diagnostics Market, providing diagnostic services to patients. Trends include the integration of digital pathology, point-of-care diagnostics, and a shift towards personalized medicine for more effective patient care.
- Contract Research Organizations (CROs): Contract Research Organizations play a pivotal role in clinical research and drug development, utilizing tissue diagnostics for robust trial outcomes. Trends involve increased outsourcing of diagnostic services, adoption of advanced imaging techniques, and customization of diagnostic solutions for research studies.
- Pharmaceutical Organizations: Pharmaceutical organizations leverage tissue diagnostics to enhance drug development and clinical trials. Trends include a growing emphasis on companion diagnostics, biomarker identification for targeted therapies, and collaborations with diagnostic companies to streamline the drug development process.
Report Scope
| Feature of the Report | Details |
| Market Size in 2023 | USD 1,244.2 Million |
| Projected Market Size in 2032 | USD 2,375.4 Million |
| Market Size in 2022 | USD 1,167.3 Million |
| CAGR Growth Rate | 7.4% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Technology, Application, End Users and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | Europe |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Competitive Landscape – Europe Tissue Diagnostics Market
The Europe Tissue Diagnostics Market is highly competitive, with a large number of manufacturers and retailers operating. Some of the key players in the market include:
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Siemens Healthineers
- Leica Biosystems Nussloch GmbH
- Becton Dickinson and Company (BD)
- Sysmex Corporation
- Illumina Inc.
- PerkinElmer Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Hologic Inc.
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
Emerging players like Guardant Health and Foundation Medicine are adopting innovative technologies such as liquid biopsies and next-generation sequencing to enter the Europe Tissue Diagnostics Market. Their focus on precision medicine and molecular diagnostics contributes to the market’s evolving landscape.
Established leaders, including Roche Diagnostics and Thermo Fisher Scientific, dominate the Europe Tissue Diagnostics Market. With extensive R&D, diverse product portfolios, and strategic acquisitions, they maintain market dominance. Collaborations and continuous advancements ensure a comprehensive suite of tissue diagnostic solutions, reinforcing their market leadership.
The Europe Tissue Diagnostics Market is segmented as follows:
By Technology
- In Situ Hybridization
- Consumables
- Instruments
- Software
- Immunohistochemistry
- Instruments
- Slide Staining Systems
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Other Products
- Consumables
- Antibodies
- Reagents
- Kits
- Instruments
- Digital Pathology and workflow
- Whole Slide Imaging
- Image Analysis Informatics
- Information Management System Storage & Communication
- Primary and Special Staining
- Anatomic Pathology
- Instruments
- Microtomes & Cryostat Microtomes
- Tissue Processors
- Automatic Strainers
- Other Products
- Consumables
- Reagents & Antibodies
- Probes & Kits
- Others
By Application
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Gastric Cancer
- Other Cancer
By End Users
- Research Laboratories
- Hospitals
- Contract Research Organizations (CROs)
- Pharmaceutical Organizations
Regional Coverage:
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Europe Tissue Diagnostics Market, (2024 – 2033) (USD Million)
- 2.2 Europe Tissue Diagnostics Market: snapshot
- Chapter 3. Europe Tissue Diagnostics Market – Industry Analysis
- 3.1 Europe Tissue Diagnostics Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Technological Advancements
- 3.2.2 Increasing Incidence of Chronic Diseases
- 3.2.3 Aging Population
- 3.2.4 Rising Awareness and Patient Demand
- 3.2.5 Telehealth Integration
- 3.2.6 Collaboration and Research Opportunities
- 3.2.7 Government Initiatives and Funding
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Technology
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End Users
- Chapter 4. Europe Tissue Diagnostics Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Europe Tissue Diagnostics Market: Company Market Share, 2022
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Europe Tissue Diagnostics Market – Technology Analysis
- 5.1 Europe Tissue Diagnostics Market Overview: By Technology
- 5.1.1 Europe Tissue Diagnostics Market Share, By Technology, 2022 and – 2033
- 5.2 In Situ Hybridization
- 5.2.1 Europe Tissue Diagnostics Market by In Situ Hybridization, 2024 – 2033 (USD Million)
- 5.3 Consumables
- 5.3.1 Europe Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Million)
- 5.4 Instruments
- 5.4.1 Europe Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Million)
- 5.5 Software
- 5.5.1 Europe Tissue Diagnostics Market by Software, 2024 – 2033 (USD Million)
- 5.6 Immunohistochemistry
- 5.6.1 Europe Tissue Diagnostics Market by Immunohistochemistry, 2024 – 2033 (USD Million)
- 5.7 Instruments
- 5.7.1 Europe Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Million)
- 5.8 Slide Staining Systems
- 5.8.1 Europe Tissue Diagnostics Market by Slide Staining Systems, 2024 – 2033 (USD Million)
- 5.9 Tissue Microarrays
- 5.9.1 Europe Tissue Diagnostics Market by Tissue Microarrays, 2024 – 2033 (USD Million)
- 5.10 Tissue Processing Systems
- 5.10.1 Europe Tissue Diagnostics Market by Tissue Processing Systems, 2024 – 2033 (USD Million)
- 5.11 Slide Scanners
- 5.11.1 Europe Tissue Diagnostics Market by Slide Scanners, 2024 – 2033 (USD Million)
- 5.12 Other Products
- 5.12.1 Europe Tissue Diagnostics Market by Other Products, 2024 – 2033 (USD Million)
- 5.13 Consumables
- 5.13.1 Europe Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Million)
- 5.14 Antibodies
- 5.14.1 Europe Tissue Diagnostics Market by Antibodies, 2024 – 2033 (USD Million)
- 5.15 Reagents
- 5.15.1 Europe Tissue Diagnostics Market by Reagents, 2024 – 2033 (USD Million)
- 5.16 Kits
- 5.16.1 Europe Tissue Diagnostics Market by Kits, 2024 – 2033 (USD Million)
- 5.17 Digital Pathology and Workflow
- 5.17.1 Europe Tissue Diagnostics Market by Digital Pathology and Workflow, 2024 – 2033 (USD Million)
- 5.18 Whole Slide Imaging
- 5.18.1 Europe Tissue Diagnostics Market by Whole Slide Imaging, 2024 – 2033 (USD Million)
- 5.19 Image Analysis Informatics
- 5.19.1 Europe Tissue Diagnostics Market by Image Analysis Informatics, 2024 – 2033 (USD Million)
- 5.20 Information Management System Storage & Communication
- 5.20.1 Europe Tissue Diagnostics Market by Information Management System Storage & Communication, 2024 – 2033 (USD Million)
- 5.21 Primary and Special Staining
- 5.21.1 Europe Tissue Diagnostics Market by Primary and Special Staining, 2024 – 2033 (USD Million)
- 5.22 Anatomic Pathology
- 5.22.1 Europe Tissue Diagnostics Market by Anatomic Pathology, 2024 – 2033 (USD Million)
- 5.23 Instruments
- 5.23.1 Europe Tissue Diagnostics Market by Instruments, 2024 – 2033 (USD Million)
- 5.24 Microtomes & Cryostat Microtomes
- 5.24.1 Europe Tissue Diagnostics Market by Microtomes & Cryostat Microtomes, 2024 – 2033 (USD Million)
- 5.25 Tissue Processors
- 5.25.1 Europe Tissue Diagnostics Market by Tissue Processors, 2024 – 2033 (USD Million)
- 5.26 Automatic Strainers
- 5.26.1 Europe Tissue Diagnostics Market by Automatic Strainers, 2024 – 2033 (USD Million)
- 5.27 Other Products
- 5.27.1 Europe Tissue Diagnostics Market by Other Products, 2024 – 2033 (USD Million)
- 5.28 Consumables
- 5.28.1 Europe Tissue Diagnostics Market by Consumables, 2024 – 2033 (USD Million)
- 5.29 Reagents & Antibodies
- 5.29.1 Europe Tissue Diagnostics Market by Reagents & Antibodies, 2024 – 2033 (USD Million)
- 5.30 Probes & Kits
- 5.30.1 Europe Tissue Diagnostics Market by Probes & Kits, 2024 – 2033 (USD Million)
- 5.31 Others
- 5.31.1 Europe Tissue Diagnostics Market by Others, 2024 – 2033 (USD Million)
- 5.1 Europe Tissue Diagnostics Market Overview: By Technology
- Chapter 6. Europe Tissue Diagnostics Market – Application Analysis
- 6.1 Europe Tissue Diagnostics Market Overview: By Application
- 6.1.1 Europe Tissue Diagnostics Market Share, By Application, 2022 and – 2033
- 6.2 Prostate Cancer
- 6.2.1 Europe Tissue Diagnostics Market by Prostate Cancer, 2024 – 2033 (USD Million)
- 6.3 Breast Cancer
- 6.3.1 Europe Tissue Diagnostics Market by Breast Cancer, 2024 – 2033 (USD Million)
- 6.4 Lung Cancer
- 6.4.1 Europe Tissue Diagnostics Market by Lung Cancer, 2024 – 2033 (USD Million)
- 6.5 Gastric Cancer
- 6.5.1 Europe Tissue Diagnostics Market by Gastric Cancer, 2024 – 2033 (USD Million)
- 6.6 Other Cancer
- 6.6.1 Europe Tissue Diagnostics Market by Other Cancer, 2024 – 2033 (USD Million)
- 6.1 Europe Tissue Diagnostics Market Overview: By Application
- Chapter 7. Europe Tissue Diagnostics Market – End Users Analysis
- 7.1 Europe Tissue Diagnostics Market Overview: By End Users
- 7.1.1 Europe Tissue Diagnostics Market Share, By End Users, 2022 and – 2033
- 7.2 Research Laboratories
- 7.2.1 Europe Tissue Diagnostics Market by Research Laboratories, 2024 – 2033 (USD Million)
- 7.3 Hospitals
- 7.3.1 Europe Tissue Diagnostics Market by Hospitals, 2024 – 2033 (USD Million)
- 7.4 Contract Research Organizations (CROs)
- 7.4.1 Europe Tissue Diagnostics Market by Contract Research Organizations (CROs), 2024 – 2033 (USD Million)
- 7.5 Pharmaceutical Organizations
- 7.5.1 Europe Tissue Diagnostics Market by Pharmaceutical Organizations, 2024 – 2033 (USD Million)
- 7.1 Europe Tissue Diagnostics Market Overview: By End Users
- Chapter 8. Europe Tissue Diagnostics Market – Regional Analysis
- 8.1 Europe Tissue Diagnostics Market Regional Overview
- 8.2 Europe Tissue Diagnostics Market Share, by Region, 2022 & – 2033 (USD Million)
- 8.3. Europe
- 8.3.1 Europe Europe Tissue Diagnostics Market, 2024 – 2033 (USD Million)
- 8.3.1.1 Europe Europe Tissue Diagnostics Market, by Country, 2024 – 2033 (USD Million)
- 8.3.1 Europe Europe Tissue Diagnostics Market, 2024 – 2033 (USD Million)
- 8.4 Europe Europe Tissue Diagnostics Market, by Technology, 2024 – 2033
- 8.4.1 Europe Europe Tissue Diagnostics Market, by Technology, 2024 – 2033 (USD Million)
- 8.5 Europe Europe Tissue Diagnostics Market, by Application, 2024 – 2033
- 8.5.1 Europe Europe Tissue Diagnostics Market, by Application, 2024 – 2033 (USD Million)
- 8.6 Europe Europe Tissue Diagnostics Market, by End Users, 2024 – 2033
- 8.6.1 Europe Europe Tissue Diagnostics Market, by End Users, 2024 – 2033 (USD Million)
- Chapter 9. Company Profiles
- 9.1 Roche Diagnostics Corporation
- 9.1.1 Overview
- 9.1.2 Financials
- 9.1.3 Product Portfolio
- 9.1.4 Business Strategy
- 9.1.5 Recent Developments
- 9.2 Thermo Fisher Scientific Inc.
- 9.2.1 Overview
- 9.2.2 Financials
- 9.2.3 Product Portfolio
- 9.2.4 Business Strategy
- 9.2.5 Recent Developments
- 9.3 Abbott Laboratories
- 9.3.1 Overview
- 9.3.2 Financials
- 9.3.3 Product Portfolio
- 9.3.4 Business Strategy
- 9.3.5 Recent Developments
- 9.4 Danaher Corporation
- 9.4.1 Overview
- 9.4.2 Financials
- 9.4.3 Product Portfolio
- 9.4.4 Business Strategy
- 9.4.5 Recent Developments
- 9.5 Agilent Technologies Inc.
- 9.5.1 Overview
- 9.5.2 Financials
- 9.5.3 Product Portfolio
- 9.5.4 Business Strategy
- 9.5.5 Recent Developments
- 9.6 Bio-Rad Laboratories Inc.
- 9.6.1 Overview
- 9.6.2 Financials
- 9.6.3 Product Portfolio
- 9.6.4 Business Strategy
- 9.6.5 Recent Developments
- 9.7 Siemens Healthineers
- 9.7.1 Overview
- 9.7.2 Financials
- 9.7.3 Product Portfolio
- 9.7.4 Business Strategy
- 9.7.5 Recent Developments
- 9.8 Leica Biosystems Nussloch GmbH
- 9.8.1 Overview
- 9.8.2 Financials
- 9.8.3 Product Portfolio
- 9.8.4 Business Strategy
- 9.8.5 Recent Developments
- 9.9 Becton Dickinson and Company (BD)
- 9.9.1 Overview
- 9.9.2 Financials
- 9.9.3 Product Portfolio
- 9.9.4 Business Strategy
- 9.9.5 Recent Developments
- 9.10 Sysmex Corporation
- 9.10.1 Overview
- 9.10.2 Financials
- 9.10.3 Product Portfolio
- 9.10.4 Business Strategy
- 9.10.5 Recent Developments
- 9.11 Illumina Inc.
- 9.11.1 Overview
- 9.11.2 Financials
- 9.11.3 Product Portfolio
- 9.11.4 Business Strategy
- 9.11.5 Recent Developments
- 9.12 PerkinElmer Inc.
- 9.12.1 Overview
- 9.12.2 Financials
- 9.12.3 Product Portfolio
- 9.12.4 Business Strategy
- 9.12.5 Recent Developments
- 9.13 Merck KGaA
- 9.13.1 Overview
- 9.13.2 Financials
- 9.13.3 Product Portfolio
- 9.13.4 Business Strategy
- 9.13.5 Recent Developments
- 9.14 Cell Signaling Technology Inc.
- 9.14.1 Overview
- 9.14.2 Financials
- 9.14.3 Product Portfolio
- 9.14.4 Business Strategy
- 9.14.5 Recent Developments
- 9.15 Hologic Inc.
- 9.15.1 Overview
- 9.15.2 Financials
- 9.15.3 Product Portfolio
- 9.15.4 Business Strategy
- 9.15.5 Recent Developments
- 9.16 Others.
- 9.16.1 Overview
- 9.16.2 Financials
- 9.16.3 Product Portfolio
- 9.16.4 Business Strategy
- 9.16.5 Recent Developments
- 9.1 Roche Diagnostics Corporation
List Of Figures
Figures No 1 to 51
List Of Tables
Tables No 1 to 5
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2032
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Siemens Healthineers
- Leica Biosystems Nussloch GmbH
- Becton Dickinson and Company (BD)
- Sysmex Corporation
- Illumina Inc.
- PerkinElmer Inc.
- Merck KGaA
- Cell Signaling Technology Inc.
- Hologic Inc.
- Others
FAQs
The “Prostate Cancer” had the largest share in the global market for Europe Tissue Diagnostics.
The key factors driving the Market are Increasing Incidence of Chronic Diseases, Aging Population, Government Initiatives and Funding, Integration of Artificial Intelligence (AI), Collaborations and Research Partnerships, Advancements in Technology And Collaborations and Strategic Partnerships.
The “In Situ Hybridization” category dominated the market in 2022.
The key players in the market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Siemens Healthineers, Leica Biosystems Nussloch GmbH , Becton Dickinson and Company (BD), Sysmex Corporation, Illumina Inc., PerkinElmer Inc., Merck KGaA, Cell Signaling Technology Inc., Hologic Inc., Others.
The global market is projected to grow at a CAGR of 7.4% during the forecast period, 2023-2032.
The Europe Tissue Diagnostics Market size was valued at USD 1,244.2 Million in 2023.